½ÃÀ庸°í¼­
»óǰÄÚµå
1535660

OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå : Á¦Ç° À¯Çüº°, Á¡µµº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2024-2032³â)

OTC Dry Eye Drops Market - By Product Type (Preservative, Preservative-free), Type (Branded, Generics), Viscosity (Low, High), Distribution Channel (Online Pharmacies, Retail Pharmacies) - Global Forecast (2024 - 2032)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀåÀº 2024-2032³â CAGR 7.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, À̰ÍÀº ÁÖ·Î ¾È±¸°ÇÁ¶Áõ ÁúȯÀÇ ÀÌȯÀ² »ó½Â¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­¿Í Àå½Ã°£ ½ºÅ©¸° »ç¿ëÀ¸·Î ÀÎÇØ ¾È°ú Áúȯ »ç·Ê°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, 2022³â ¹Ì±¹ ¾È°úÇÐȸ Á¶»ç¿¡ µû¸£¸é ¾à 1,600¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¾È±¸°ÇÁ¶ÁõÀ» ¾Î°í ÀÖÀ¸¸ç, ÀÌ ÁõÈıºÀº ³ë³âÃþ¿¡¼­ ´õ ¸¹ÀÌ ¹ß»ýÇÑ´Ù°í ÇÕ´Ï´Ù.

ƯÈ÷ Àå½Ã°£ÀÇ µðÁöÅÐ È­¸é ³ëÃâÀ̳ª ȯ°æ ¿À¿° ¹°Áú°ú °ü·ÃµÈ ´«ÀÇ ¿°Áõ°ú °°Àº Áõ»óÀ» ºü¸£°Ô ¿ÏÈ­ÇϰíÀÚ ÇÏ´Â »ç¶÷µé »çÀÌ¿¡¼­ OTC ¾È±¸°ÇÁ¶Áõ ¾È¾à¿¡ ´ëÇÑ ¼±È£µµ°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦Ç° Çõ½Å°ú ±â¼ú ¹ßÀüµµ ½ÃÀå Á¡À¯À²À» È®´ëÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº È¿´ÉÀ» ³ôÀ̰í, ´õ ¿À·¡ Áö¼ÓµÇ¸ç, ºÎÀÛ¿ëÀÌ ÀûÀº ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦¸¦ Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ¹«¹æºÎÁ¦ ¹× ÀúÀڱؼº ´ë¾ÈÀÇ µîÀåÀº Á¦Ç°ÀÇ ¸Å·ÂÀ» ´õ¿í ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ´« °Ç°­¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´Ù¾çÇÑ Á¦Ç°±ºÀÇ °¡¿ë¼º°ú ÇÔ²² ¾÷°èÀÇ Àü¸ÁÀ» Çü¼ºÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹«¹æºÎÁ¦ ºÐ¾ß´Â ÁÖ·Î ´« °Ç°­¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ Àνİú ¹Î°¨µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ³ôÀº ¼ö¿ä¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ¾È¾à¿¡ ÇÔÀ¯µÈ ¹æºÎÁ¦´Â ¹ÚÅ׸®¾ÆÀÇ ¹ø½ÄÀ» ¸·´Â È¿°ú°¡ ÀÖÁö¸¸, ƯÈ÷ ¹Î°¨ÇÑ ´«À̳ª ÀÚÁÖ »ç¿ëÇØ¾ß ÇÏ´Â »ç¶÷µé¿¡°Ô´Â °ÇÁ¶ÇÔ°ú ¿°ÁõÀ» ¾ÇÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù. ¹æºÎÁ¦°¡ ÇÔÀ¯µÇÁö ¾ÊÀº Á¦ÇüÀº ´õ ¾ÈÀüÇÑ ´ë¾ÈÀ» Á¦°øÇϰí Ãß°¡ÀûÀÎ ÀÚ±ØÀÇ À§ÇèÀ» ÁÙ¿©ÁÖ¸ç, Á¤±âÀûÀ¸·Î »ç¿ëÇϱ⿡ ´õ ÀûÇÕÇÕ´Ï´Ù. °³ÀÎÈ­µÈ ¸ÂÃãÇü ¾ÆÀÌÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Ãß¼¼´Â ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Á¦³×¸¯ ÀǾàǰÀº ºê·£µå ÀǾàǰ¿¡ ºñÇØ ºñ¿ë È¿À²ÀûÀ̰í Á¢±Ù¼ºÀÌ ¶Ù¾î³ª 2032³â±îÁö ÁÖ¸ñÇÒ ¸¸ÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀº ºê·£µå ÀǾàǰ°ú µ¿µîÇÑ È¿´É°ú ¾ÈÀü¼ºÀ» °¡Áö¸é¼­µµ °¡°ÝÀº ´õ Àú·ÅÇÕ´Ï´Ù. ÀÇ·áºñ°¡ »ó½ÂÇÏ°í ¼ÒºñÀÚµéÀÌ º¸´Ù Àú·ÅÇÑ Ä¡·á ¿É¼ÇÀ» ã´Â °¡¿îµ¥, Á¦³×¸¯ ÀǾàǰÀº ǰÁú¿¡ ´ëÇÑ Å¸Çù ¾øÀÌ ½Ç¿ëÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¼¿ÇÁ ¸ÞµðÄÉÀ̼Ç(self-medication) Áõ°¡¿Í ¼Ò¸ÅÁ¡ ¹× ¿Â¶óÀΠä³Î¿¡¼­ Á¦³×¸¯ ÀǾàǰÀ» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°ÔµÈ °Íµµ Á¦³×¸¯ ÀǾàǰÀÇ Àα⠻ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«ÀÇ OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à »ê¾÷Àº ´« °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¾È±¸°ÇÁ¶Áõ ¹ßº´·ü Áõ°¡, ÇコÄɾî Á¦Ç°¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë µîÀ» ¹è°æÀ¸·Î 2032³â±îÁö Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºê¶óÁú°ú ¸ß½ÃÄÚ¿Í °°Àº ±¹°¡ÀÇ °æÁ¦ °³¼±À¸·Î °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡Çϸ鼭 ´õ ¸¹Àº ¼ÒºñÀÚµéÀÌ ¾È°ú Á¦Ç°À» ±¸¸ÅÇÒ ¼ö ÀÖ´Â ¿©·ÂÀÌ »ý°å½À´Ï´Ù. ¶ÇÇÑ ±Þ¼ÓÇÑ µµ½ÃÈ­¿Í ÀÌ¿¡ µû¸¥ ±¹¹ÎµéÀÇ ½ºÅ©¸° »ç¿ë ½Ã°£ Áõ°¡´Â ¾È±¸°ÇÁ¶ÁõÀ» ¾ÇÈ­½ÃÄÑ È¿°úÀûÀÎ OTC ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. À¯Åë¸Á È®´ë¿Í ±¹Á¦ ºê·£µåÀÇ ÁøÃâ·Î ÀÌ Áö¿ª ¼ÒºñÀÚµéÀÌ ´Ù¾çÇÑ Á¦Ç°À» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¾È±¸°ÇÁ¶ÁõÀÇ À¯º´·ü »ó½Â
      • ÀǽÄÀÇ Çâ»ó°ú ÀÚ±â ÇコÄÉ¾î ½Çõ
      • ½ºÅ©¸° ŸÀÓ°ú µðÁöÅÐ ±â±â »ç¿ëÀÇ Áõ°¡
      • Á¦Ç° ó¹æÀÇ ±â¼úÀû Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ºÎÀÛ¿ë°ú ¾Ë·¹¸£±â ¹ÝÀÀ
      • ´ëü Ä¡·áÀÇ ÀÌ¿ë °¡´É¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
    • ÄÚ¾î ±â¼ú
    • ÀÎÁ¢ ±â¼ú
  • °¡°Ý ºÐ¼®(2023³â)
    • Áö¿ªº°
    • ÁÖ¿ä ±â¾÷º°
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¹æºÎÁ¦
  • ¹æºÎÁ¦ ÇÁ¸®

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºê·£µå
  • Á¦³×¸¯

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¡µµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀúÁ¡µµ
  • °íÁ¡µµ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ±âŸ À¯Åë ä³Î

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • AbbVie, Inc.
  • Alcon
  • Allergan plc
  • Altaire Pharmaceutical Inc.
  • Bausch Health Companies Inc.
  • IDEX CORPORATION
  • Johnson & Johnson
  • Medicom Healthcare Pvt Ltd.
  • Novartis AG
  • OASIS
  • Prestige Consumer Healthcare Inc.
  • Rohto Pharmaceutical Co., Ltd.
  • Similasan Corporation
  • Sentiss Pharma Private Limited
KSA 24.08.26

The OTC dry eye drops market is anticipated to record 7.6% CAGR between 2024 and 2032, primarily driven by the rising incidence of dry eye disease. Aging populations and prolonged screen time is leading to an increase in eye condition cases, bolstering the demand for over-the-counter remedies. As per a study by the American Academy of Ophthalmology in 2022, nearly 16 million Americans suffer from dry eye disease, and this syndrome is found to be more prevalent in the elderly.

There is a surge in preference for OTC dry eye drops, especially among those seeking quick relief from symptoms like eye irritation, often linked to extended digital screen exposure and environmental pollutants. Further, product innovation and technological advancements are also expanding the market share. Manufacturers are introducing formulations with heightened efficacy, longer-lasting relief, and fewer side effects. The advent of preservative-free and hypoallergenic options is broadening the product appeal. The growing consumer awareness regarding eye health, in tandem with availability of diverse product range, will shape the industry outlook.

The overall OTC dry eye drops market is segmented based on product type, type, viscosity, distribution channel, and region.

The preservative-free segment is witnessing high demand, primarily due to increasing consumer awareness and sensitivity regarding eye health. Preservatives in eye drops, while effective at preventing bacterial growth, can sometimes exacerbate dryness and irritation, especially in individuals with sensitive eyes or those requiring frequent use. Preservative-free formulations offer a safer alternative, reducing the risk of additional irritation and making them more suitable for regular use. The broader trend towards personalized and gentle eye care solutions will favor the segment growth.

The generic segment is slated to hold a notable market share by 2032, due to their cost-effectiveness and accessibility compared to branded counterparts. Generic products offer similar efficacy and safety profiles as their branded equivalents but at a lower price point. As healthcare costs rise and consumers seek more affordable treatment options, generics provide a practical solution without compromising on quality. Additionally, the growing trend towards self-medication and the increasing availability of generics in retail and online channels contribute to their rising popularity.

OTC dry eye drops industry size in Latin America will expand at a significant pace through 2032, driven by increasing awareness about eye health, rising incidences of dry eye syndrome, and expanding access to healthcare products. Economic improvements in countries like Brazil and Mexico have led to higher disposable incomes, enabling more consumers to afford eye care products. Furthermore, rapid urbanization and the resulting increase in screen time among the population have exacerbated dry eye symptoms, boosting demand for effective OTC solutions. The enhanced distribution networks and the entry of international brands, making a wider range of products readily available to consumers across the region, are bolstering the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of dry eye syndrome
      • 3.2.1.2 Growing awareness and self-care practices
      • 3.2.1.3 Increased screen time and digital device usage
      • 3.2.1.4 Technological advancements in product formulations
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects and allergic reactions
      • 3.2.2.2 Availability of alternative treatments
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Pricing analysis, 2023
    • 3.6.1 By region
    • 3.6.2 By key player
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Preservative
  • 5.3 Preservative-free

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Viscosity, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Low viscosity
  • 7.3 High viscosity

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Online pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie, Inc.
  • 10.2 Alcon
  • 10.3 Allergan plc
  • 10.4 Altaire Pharmaceutical Inc.
  • 10.5 Bausch Health Companies Inc.
  • 10.6 IDEX CORPORATION
  • 10.7 Johnson & Johnson
  • 10.8 Medicom Healthcare Pvt Ltd.
  • 10.9 Novartis AG
  • 10.10 OASIS
  • 10.11 Prestige Consumer Healthcare Inc.
  • 10.12 Rohto Pharmaceutical Co., Ltd.
  • 10.13 Similasan Corporation
  • 10.14 Sentiss Pharma Private Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦